-$0.55 Earnings Per Share Expected for Inflarx NV (NASDAQ:IFRX) This Quarter

Wall Street analysts expect Inflarx NV (NASDAQ:IFRX) to report earnings per share of ($0.55) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Inflarx’s earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.60). Inflarx reported earnings of ($0.12) per share in the same quarter last year, which indicates a negative year over year growth rate of 358.3%. The business is scheduled to issue its next earnings results on Thursday, August 8th.

On average, analysts expect that Inflarx will report full year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($2.27) to ($1.86). For the next financial year, analysts anticipate that the business will report earnings of ($2.83) per share, with EPS estimates ranging from ($4.02) to ($2.16). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Inflarx.

Inflarx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, May 23rd. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.19.

A number of research firms have recently weighed in on IFRX. Raymond James restated a “buy” rating on shares of Precision Drilling in a report on Wednesday, June 5th. Guggenheim lowered shares of Inflarx from a “buy” rating to a “neutral” rating and lowered their price target for the company from $65.00 to $6.00 in a report on Wednesday, June 5th. Robert W. Baird lowered shares of Inflarx from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $58.00 to $6.00 in a report on Wednesday, June 5th. JPMorgan Chase & Co. set a $69.00 price target on shares of Helmerich & Payne and gave the company a “buy” rating in a report on Wednesday, June 5th. Finally, Svb Leerink lowered shares of Inflarx from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 5th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. Inflarx presently has a consensus rating of “Hold” and an average target price of $15.72.

Shares of Inflarx stock traded down $0.09 on Wednesday, reaching $3.06. 684,700 shares of the company were exchanged, compared to its average volume of 847,545. The firm has a market cap of $82.05 million, a P/E ratio of -2.19 and a beta of -1.52. Inflarx has a one year low of $2.91 and a one year high of $53.10. The firm’s 50-day moving average is $7.87.

Several institutional investors have recently modified their holdings of the business. Alpine Global Management LLC acquired a new stake in Inflarx during the 2nd quarter worth approximately $95,000. Spark Investment Management LLC bought a new position in Inflarx during the first quarter valued at approximately $359,000. Paloma Partners Management Co bought a new position in Inflarx during the fourth quarter valued at approximately $526,000. Bank of America Corp DE bought a new position in Inflarx during the fourth quarter valued at approximately $657,000. Finally, Artisan Partners Limited Partnership raised its position in Inflarx by 36.1% during the first quarter. Artisan Partners Limited Partnership now owns 52,197 shares of the company’s stock valued at $1,973,000 after acquiring an additional 13,834 shares in the last quarter. Institutional investors and hedge funds own 55.89% of the company’s stock.

About Inflarx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Recommended Story: What is the downside to momentum investing?

Get a free copy of the Zacks research report on Inflarx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.